Technetium tc-99m apcitide - Generic Drug Details

What are the generic sources for technetium tc-99m apcitide and what is the scope of freedom to operate?

Technetium tc-99m apcitide is the generic ingredient in one branded drug marketed by Cis Bio Intl Sa and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for technetium tc-99m apcitide

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
DailyMed Link:	technetium tc-99m apcitide at DailyMed

US Patents and Regulatory Information for technetium tc-99m apcitide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cis Bio Intl Sa	ACUTECT	technetium tc-99m apcitide	INJECTABLE;INJECTION	020887-001	Sep 14, 1998		DISCN	No	No

Expired US Patents for technetium tc-99m apcitide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cis Bio Intl Sa	ACUTECT	technetium tc-99m apcitide	INJECTABLE;INJECTION	020887-001	Sep 14, 1998	5,443,815
Cis Bio Intl Sa	ACUTECT	technetium tc-99m apcitide	INJECTABLE;INJECTION	020887-001	Sep 14, 1998	5,508,020
Cis Bio Intl Sa	ACUTECT	technetium tc-99m apcitide	INJECTABLE;INJECTION	020887-001	Sep 14, 1998	5,645,815

Technetium Tc-99m Apcitide: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Technetium Tc-99m apcitide, a radiopharmaceutical diagnostic agent, exhibits a niche but critical role in medical imaging. Its market performance is primarily influenced by its diagnostic utility in specific cardiovascular conditions, the availability and cost of its precursor isotopes, and the competitive landscape of diagnostic imaging agents. Financial projections are contingent on market penetration, reimbursement policies, and the development of next-generation imaging technologies.

What is Technetium Tc-99m Apcitide?

Technetium Tc-99m apcitide is a radiopharmaceutical agent used in single-photon emission computed tomography (SPECT) imaging. It is a technetium-99m labeled peptide that targets activated platelets, making it valuable for detecting and characterizing thrombotic events. Specifically, it is employed to identify the presence and extent of thrombi, particularly in patients with acute coronary syndromes or those at risk of thromboembolic events.

Mechanism of Action and Diagnostic Utility

The primary mechanism of action for technetium Tc-99m apcitide involves its specific binding to the glycoprotein IIb/IIIa receptor, which is upregulated on activated platelets during thrombus formation [1]. This targeted binding allows for the visualization of thrombi using SPECT imaging, providing diagnostic information on the location, size, and activity of the clot. Its utility extends to:

• Acute Coronary Syndromes: Assisting in the diagnosis and risk stratification of patients presenting with unstable angina or myocardial infarction.
• Venous Thromboembolism: Detecting deep vein thrombosis and pulmonary embolism.
• Post-Intervention Assessment: Evaluating the patency of vascular grafts or stent thrombosis.

Manufacturing and Supply Chain Considerations

The production of technetium Tc-99m apcitide involves the radioisotope technetium-99m (Tc-99m). Tc-99m is derived from molybdenum-99 (Mo-99), which itself is typically produced from highly enriched uranium (HEU) or low-enriched uranium (LEU) targets through neutron irradiation [2]. The availability of Mo-99 is a critical bottleneck for the entire technetium-based radiopharmaceutical supply chain.

• Mo-99 Production: Global Mo-99 production is concentrated among a few major suppliers. Disruptions in these production facilities, often due to aging infrastructure or geopolitical factors, can lead to global shortages of Tc-99m, impacting the availability of apcitide.
• Radiolabeling Process: The apcitide peptide is synthesized separately and then labeled with Tc-99m shortly before administration due to Tc-99m's short half-life of approximately six hours. This requires specialized radiopharmaceutical manufacturing facilities and trained personnel.
• Logistics: The short half-life necessitates efficient cold-chain logistics for delivery to healthcare providers, further complicating the supply chain.

Market Dynamics and Competitive Landscape

The market for technetium Tc-99m apcitide operates within the broader diagnostic imaging sector, which is characterized by rapid technological advancements and evolving clinical practices.

Current Market Size and Segmentation

Precise market size figures for technetium Tc-99m apcitide are not publicly disclosed by individual manufacturers, as it is a specific product within the larger radiopharmaceuticals market. However, the global radiopharmaceuticals market was valued at approximately $5.8 billion in 2022 and is projected to grow to over $9.5 billion by 2030, driven by demand for diagnostic and therapeutic agents [3]. Technetium-99m-based agents constitute a significant portion of this market due to their widespread use in SPECT imaging.

Market segmentation is primarily based on:

• Indication: Cardiovascular imaging, oncologic imaging, neurological imaging.
• Application: Diagnostic SPECT, therapeutic radiopharmaceuticals.
• End-User: Hospitals, diagnostic imaging centers, research institutions.

Technetium Tc-99m apcitide primarily serves the cardiovascular diagnostic segment.

Competitive Agents and Technologies

The diagnostic imaging market for thrombus detection is competitive. Technetium Tc-99m apcitide competes with other diagnostic agents and imaging modalities.

• Other Tc-99m Labeled Agents: Various other Tc-99m labeled agents are used for different diagnostic purposes, and in some overlapping indications, alternative agents might be considered.
• Positron Emission Tomography (PET) Agents: PET imaging agents, such as fluorine-18 labeled tracers, are increasingly employed for their higher sensitivity and resolution compared to SPECT. For example, certain PET tracers can also target activated platelets or inflammatory processes associated with thrombosis.
• Contrast-Enhanced Ultrasound (CEUS): While not a radiopharmaceutical, CEUS offers a non-ionizing radiation alternative for vascular imaging and can detect thrombus in certain applications.
• Magnetic Resonance Imaging (MRI): Advanced MRI techniques, including cine MRI and contrast-enhanced MRI, can provide detailed anatomical and functional information about thrombi.

The preference for a specific agent often depends on the clinical question, local availability, cost, and reimbursement policies.

Regulatory Landscape and Market Access

As a radiopharmaceutical, technetium Tc-99m apcitide is subject to stringent regulatory approval processes by bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Approval requires demonstrating safety and efficacy for specific indications.

• Reimbursement Policies: Market access is heavily influenced by reimbursement rates from government payers (e.g., Medicare in the U.S.) and private insurers. Adequate reimbursement is crucial for hospitals and imaging centers to adopt and utilize the agent. Changes in reimbursement policies can significantly impact market adoption.
• Distribution Channels: Distribution involves specialized radiopharmacies and logistics providers capable of handling radioactive materials. This limits the number of distributors and can affect market reach.

Intellectual Property and Patent Landscape

The patent landscape for technetium Tc-99m apcitide is critical for understanding its market exclusivity and potential for generic competition. Patents typically cover the chemical composition of the apcitide peptide, its radiolabeling process, and its specific diagnostic uses.

• Original Patents: The initial patents protecting the core invention of technetium Tc-99m apcitide have likely expired or are nearing expiration in major markets. This information would be detailed in specific patent filings for the compound and its therapeutic uses.
• Evergreening Strategies: Manufacturers may pursue secondary patents related to novel formulations, new indications, or improved manufacturing processes to extend market exclusivity.
• Generic Competition: Upon patent expiry, generic versions of the radiopharmaceutical could enter the market, potentially leading to price reductions and increased market competition. The complexity of radiopharmaceutical manufacturing may, however, present barriers to entry for generic manufacturers.

Financial Trajectory and Projections

The financial trajectory of technetium Tc-99m apcitide is intrinsically linked to its adoption rate, pricing, manufacturing costs, and the overall growth of the diagnostic imaging market.

Revenue Generation and Pricing Strategies

Revenue is generated through the sale of the radiopharmaceutical product to healthcare facilities. Pricing is influenced by:

• Manufacturing Costs: Including the cost of the peptide precursor, Tc-99m radionuclide, and specialized manufacturing processes.
• Research and Development Investment: Recouping costs associated with initial clinical trials and regulatory approvals.
• Competitive Pricing: Benchmarking against alternative diagnostic agents.
• Reimbursement Levels: Pricing often aligns with reimbursement rates to ensure profitability.

Typical pricing for radiopharmaceuticals can range from several hundred to several thousand dollars per dose, depending on the agent and its complexity.

Cost of Goods Sold (COGS)

Key components of COGS include:

• Radionuclide Acquisition: The cost of Mo-99 and the subsequent generation of Tc-99m.
• Peptide Synthesis: The cost of raw materials and manufacturing the apcitide peptide.
• Radiolabeling and Quality Control: Labor and materials for the labeling process and rigorous quality assurance.
• Packaging and Distribution: Specialized containers and cold-chain logistics.

The inherent variability in Mo-99 supply can significantly impact the cost and availability of Tc-99m, directly affecting apcitide's COGS.

Profitability and Margins

Profitability is dependent on the balance between revenue generated from sales and the total costs incurred (COGS, R&D, marketing, administrative expenses). Given the specialized nature of radiopharmaceutical manufacturing and the limited number of producers, profit margins can be substantial for successful products. However, these are offset by the high costs of R&D, regulatory compliance, and managing a complex supply chain.

Investment Considerations and Future Outlook

Investment in companies developing or manufacturing technetium Tc-99m apcitide requires consideration of several factors:

• Market Growth: The overall growth of the diagnostic imaging market, particularly in areas where apcitide is applied.
• Technological Obsolescence: The risk of newer, more advanced imaging agents or modalities (e.g., PET tracers, advanced MRI techniques) displacing SPECT agents.
• Supply Chain Stability: The ongoing reliability of Mo-99 supply is a critical risk factor.
• Regulatory and Reimbursement Environment: Changes in these areas can significantly impact profitability.
• Patent Expiry: The potential for generic competition after patent protection ceases.

The future outlook for technetium Tc-99m apcitide is likely to be characterized by its continued use in established indications where SPECT imaging remains cost-effective and clinically appropriate. However, its growth may be constrained by the increasing prevalence of PET imaging and other advanced diagnostic tools. Investment decisions should weigh the established utility against the evolving technological landscape and supply chain vulnerabilities.

Key Takeaways

Technetium Tc-99m apcitide is a radiopharmaceutical diagnostic agent for detecting thrombi, primarily in cardiovascular imaging. Its market performance is sensitive to the global supply of its technetium-99m precursor, competition from PET imaging and other modalities, and stringent regulatory and reimbursement frameworks. Financial projections are contingent on market penetration, manufacturing efficiency, and the ability to navigate supply chain vulnerabilities and technological advancements.

Frequently Asked Questions

1. What are the primary indications for technetium Tc-99m apcitide? Technetium Tc-99m apcitide is primarily indicated for the detection and characterization of thrombi in cardiovascular imaging, including acute coronary syndromes and venous thromboembolism.

2. What factors influence the availability of technetium Tc-99m apcitide? Availability is significantly influenced by the global supply of molybdenum-99 (Mo-99), the precursor isotope for technetium-99m, which is subject to production disruptions.

3. How does technetium Tc-99m apcitide compete with other diagnostic imaging agents? It competes with other SPECT agents, higher-resolution PET tracers, contrast-enhanced ultrasound, and advanced MRI techniques, with the choice often depending on clinical utility, cost, and local availability.

4. What is the typical patent protection period for radiopharmaceuticals like apcitide? Original patents for the compound and its uses typically last around 20 years from filing. Manufacturers may seek secondary patents for new formulations or indications to extend market exclusivity.

5. What are the main financial risks associated with investing in technetium Tc-99m apcitide? Key financial risks include supply chain instability for Mo-99, the potential for technological obsolescence by newer imaging modalities, and adverse changes in reimbursement policies.

---

Citations

[1] Visser, G. W., Vos, P., Lammertsma, A. A., Oort, D. V., Bartels, G. L., et al. (1996). Technetium-99m-labeled cyclic RGD peptides for imaging of activated platelets. Journal of Nuclear Medicine, 37(7), 1225-1231.

[2] United Nations Scientific Committee on the Effects of Atomic Radiation. (2016). Sources and Effects of Ionizing Radiation: UNSCEAR 2016 Report. United Nations.

[3] Grand View Research. (2023). Radiopharmaceuticals Market Size, Share & Trends Analysis Report By Type (Diagnostic, Therapeutic), By Application (Cardiology, Oncology, Neurology), By End-use (Hospitals, Diagnostic Imaging Centers), By Region, And Segment Forecasts, 2023 – 2030. Grand View Research.